



Atlantic Innovation Fund Nova Scotia

\$216.3 million

Announced AIF Investments in Nova Scotia since 2001

\$499.7 million

Total overall value of projects in Nova Scotia since 2001

The Atlantic Canada Opportunities Agency (ACOA) works to enhance Atlantic Canada's ability to carry out leading-edge R&D and bring new knowledge, new jobs and new business opportunities to the region. Launched in 2001, the Atlantic Innovation Fund (AIF) has evolved into one of ACOA's core funding programs that is helping Atlantic Canadians be more **innovative and competitive** in a **global knowledge-based economy** through the development of new ideas, products, businesses and markets.

AIF Investments in Nova Scotia, by sectors:

1 Health and Medical	28.5%
2 Information and Communications Technologies	19.4%
3 Manufacturing and Processing	18.4%
4 Biotechnology	11.9%
5 Environment	6.1%
6 Energy	6.1%
7 Aquaculture	4.0%
8 Oceans Technology	5.4%
9 Other	0.1%

Over 180*

Partnerships enabled

Over 750*

Highly qualified personnel hired/retained

\$283.4 million

Funds leveraged by AIF projects in Nova Scotia since 2001

45*

New products commercialized

\$82 million*

Revenues generated from new products/technologies

*Between 2002 and 2007

For more information, visit
www.acoa-apeco.gc.ca/aif



Atlantic Canada
Opportunities
Agency

Agence de
promotion économique
du Canada atlantique

Canada

Impacts and Investments

Delivering breakthrough vaccines

Whether it's developing a vaccine that works efficiently with a patient's immune system to treat cancer or building innovative vaccines to prevent the spread of infectious diseases, Halifax-based Immunovaccine Inc. is pursuing big ideas.

With **\$9.6 million** from the Atlantic Innovation Fund (AIF) for projects funded in 2003, 2008 and 2011, the company has patented an innovative vaccine adjuvanting platform called DepoVax™. DepoVax is a breakthrough in vaccine development because it creates a unique depot effect that attracts antigen-presenting cells to the injection site to generate a rapid and robust immune response.

With a focus on the therapeutic areas with the strongest growth potential, Immunovaccine is recognized as one of the most promising early stage biotech companies in Canada.

Related website: www.imvaccine.com

A bright idea leads to a bright future

LED Roadway Lighting Ltd. (LRL) is a world leader in the outdoor LED (Light-Emitting Diode) lighting and controls market.

With a **\$5.1 million** investment from the Atlantic Innovation Fund (AIF), the company was able to carry out the research, design and development of a prototype for a stand-alone system of streetlights as well as a retrofit model for situations where replacement of an existing set of fixtures is not feasible.

LRL's leadership is driving the adoption of LED street lighting worldwide. Headquartered in Halifax, the company's Satellite™ series street and area lighting fixtures have been installed by more than 300 municipal and utility clients in more than 25 countries.

The technology addresses a real challenge faced by municipalities worldwide – rising energy costs and significant challenges with maintaining lighting infrastructure.

Related website: www.ledroadwaylighting.com

“Immunovaccine is establishing global relationships with pharmaceutical companies and is well positioned to develop the next generation of therapeutic cancer vaccines and vaccines for infectious diseases.”

John Trizzino
CEO
Immunovaccine Inc.

“Within a three year period, LED Roadway Lighting has emerged as a global player in the field of street and area lighting. We provide a solution that delivers energy savings, improved lighting levels and the lowest total cost of ownership over 20 years.”

Charles Cartmill
President and CEO
LED Roadway Lighting Ltd.



Atlantic Canada
Opportunities
Agency

Agence de
promotion économique
du Canada atlantique

Canada